Question 1

Does Boston Trust Walden own HAE stock?

Accepted Answer

Yes. As of its Q3 2026 13F, Boston Trust Walden holds 385,355 shares of HAE (Haemonetics), worth $40.6M.

Question 2

How many shares of HAE does Boston Trust Walden own?

Accepted Answer

As of its Q3 2026 13F, Boston Trust Walden holds 385,355 shares of HAE (Haemonetics).

Question 3

What is Boston Trust Walden's HAE position worth?

Accepted Answer

As of its Q3 2026 13F, Boston Trust Walden's HAE position is worth $40.6M.

Question 4

Is Boston Trust Walden buying or selling HAE?

Accepted Answer

In Q3 2026, Boston Trust Walden reduced its HAE position by 199,793 shares (-34.1%).

Question 5

When did Boston Trust Walden first buy HAE?

Accepted Answer

Boston Trust Walden already held HAE in its Q1 2019 13F, the earliest on record, and has listed it in 31 quarterly 13F filings.

Quarter	Action	Shares	Change	Value	Weight	Price	Conviction
2026-Q3 Latest	Decreased	385,355	-34.1%	$40.6M	0.3%	$105.30	0
2026-Q2	Increased	585,148	+16.6%	$43.9M	0.3%	$75.00	40
2026-Q1	Decreased	501,885	-13.6%	$28.3M	0.2%	$56.36	0
2025-Q4	Decreased	580,650	-39.3%	$46.5M	0.4%	$80.15	0
2025-Q3	Decreased	956,690	-12.2%	$46.6M	0.3%	$48.74	0
2025-Q2	Decreased	1.1M	-2.5%	$81.3M	0.6%	$74.61	0
2025-Q1	Increased	1.1M	+22.1%	$71.1M	0.5%	$63.55	50
2024-Q4	Increased	915,722	+13.1%	$71.5M	0.5%	$78.08	47
2024-Q3	Increased	809,608	+13.8%	$65.1M	0.5%	$80.38	40

HAHAE